Skip to main content
. 2021 Jan 20;38(2):137–146. doi: 10.1007/s40266-020-00829-z

Table 2.

Responder analysis in patients aged ≥ 65 yearsa (full analysis set)

Analysis, n (%) Placebo (N = 220) Vibegron (N = 242) Tolterodine (N = 166)
≥ 75% reduction in UUI episodesb 50 (29.8) 96 (50.0)** 55 (43.0)*
50% reduction in urgency episodes 63 (28.8) 94 (38.7)* 49 (29.5)

UUI urge urinary incontinence

aOn a 7-day diary at week 12

bFull analysis set for incontinence (placebo, N = 168; vibegron, N = 192; tolterodine, N = 128)

*P < 0.05; **P < 0.001 vs. placebo